RECURRENT FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR T-Cell attack on tough blood cancers shows early promise
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New combo therapy aims to boost lymphoma treatment and cut side effects
Disease control Recruiting nowThis study tests whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has returned or not responded to prior therapy. About 22 adults with grade 1-3a lymphoma will receive the combination. The goal is to improve cancer remission …
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC